Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2012-01-12
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 35
- Registration Number
- NCT01508949
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Frederiksberg C, Denmark
Comparison of Two Liraglutide Formulations in Healthy Volunteers
- First Posted Date
- 2012-01-12
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 22
- Registration Number
- NCT01508897
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neu-Ulm, Germany
Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency
Completed
- Conditions
- MenopausePostmenopausal Vaginal Atrophy
- Interventions
- Drug: estradiol, 25 mcg
- First Posted Date
- 2012-01-11
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1613
- Registration Number
- NCT01507454
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany
Diabetes Attitudes Wishes and Needs
Completed
- Conditions
- Healthcare ProfessionalsDiabetes Mellitus, Type 1DiabetesRelatives to/Carers of PatientsDiabetes Mellitus, Type 2
- Interventions
- Other: No treatment given
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 8985
- Registration Number
- NCT01507116
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom
Safety and Tolerability of Liraglutide in Healthy Male Volunteers
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 34
- Registration Number
- NCT01507272
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT01507337
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Healthy
- Interventions
- Drug: placebo
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT01507285
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT01507389
Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 11
- Registration Number
- NCT01507311
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Århus C, Denmark
Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries
Completed
- Conditions
- Haemophilia AHaemophilia B With InhibitorsCongenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B
- Interventions
- Other: No treatment given
- First Posted Date
- 2012-01-04
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 282
- Registration Number
- NCT01503567
- Locations
- 🇿🇦
Novo Nordisk Investigational Site, Sandton, South Africa
© Copyright 2025. All Rights Reserved by MedPath